Marisa Wexler, MS, senior science writer —

UCB’s zilucoplan and Rystiggo (rozanolixizumab) both were approved in Japan to treat adults with generalized myasthenia gravis (gMG) who lack an adequate response to steroids or other immunosuppressive treatments. “With the approval in Japan of zilucoplan and [Rystiggo], we are very proud and excited to expand our…

Treatment with the experimental therapy povetacicept (ALPN-303) reduced disease activity in a mouse model of myasthenia gravis (MG), according to data shared by its developer, Alpine Immune Sciences. Povetacicept also was tolerated well by healthy volunteers participating in a Phase 1 clinical trial. “Together, these data provide strong…

Elderly people with myasthenia gravis (MG) are at higher risk of experiencing side effects related to disease treatments, which can be fatal for patients in some cases, a new study found. In fact, treatment-related adverse effects were seen among more than 40% of patients in the study —…

Soliris (eculizumab), already approved in Japan for adults with generalized myasthenia gravis (gMG), has now become the first therapy to win approval in the Asian nation for treating children and adolescents with this type of the autoimmune condition. The expanded use was granted by the Japanese Ministry of…

The approval of Soliris (eculizumab) in the European Union now extends to children and adolescents, ages 6 to 17, with generalized myasthenia gravis (gMG). The European Commission decision covers Soliris’ use in children who have refractory disease, meaning they have failed to respond to standard treatments, and are…

A branch of the European Medicines Agency (EMA) recommended that the approval of Soliris (eculizumab) be expanded to include children and adolescents, ages 6 to 17, with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor (AChR) — the most common type of MG-driving…

People with myasthenia gravis (MG) who are positive for antibodies against the acetylcholine receptor (AChR) — the most common MG-causing antibodies — tend to have increased activation of part of the immune system called the complement cascade, according to a recent study. However, increased complement activation was not…

Vyvgart (efgartigimod alfa-fcab) is now approved in Israel for the treatment of generalized myasthenia gravis (gMG), according to its developer, Argenx. This is the second new approval for Vyvgart in gMG this year, following a similar positive decision in the U.K. in March. The therapy has…

Repeated treatment with under-the-skin efgartigimod had a consistent effect in easing symptoms of generalized myasthenia gravis (gMG), with no new safety issues identified.  That’s according to interim data from the Phase 3 extension study ADAPT-SC+ (NCT04818671), which is…

People with generalized myasthenia gravis (gMG) treated with the experimental therapy rozanolixizumab in a clinical trial generally experienced reductions in disease severity scores regardless of disease duration, prior treatments, and initial disease severity, new analyses suggest. Findings were presented by Tuan Vu, MD, of the University of South…